1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU Seeking Firms To Offer ‘Ever-Warm’ Production Capacity For Future Pandemics

 
• By Ian Schofield

The EU is drawing on lessons learned during the COVID-19 pandemic to set up a network of vaccine production capacities able to respond quickly to a surge in demand.

Coronavirus disease pandemic Europe economics impact 3D concept. European economy background: covid-19 ncov 2019 corona virus, European Union flag
The EU wants to be ready to tackle future health crises • Source: Shutterstock

The European Commission is expected to issue an invitation next month to companies wanting to take part in a project aimed at ensuring sufficient vaccine manufacturing capacity is available in the event of a future health crisis.

EU FAB is a proposed network of “ever-warm” production facilities in the EU that would be used as normal during non-crisis times but could quickly be turned to the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

EU Moment Of Truth For Obe-Cel And 10 Other New Medicines

 
• By Neena Brizmohun

Autolus’s CAR T therapy obe-cel is among the medicines that are this week due for an opinion by the European Medicines Agency on whether they should be marketed in the EU.

Blenrep’s Revival Gains Steam: EMA Decision Imminent As Japan Approves New Regimen

 
• By Neena Brizmohun

The European Medicines Agency is due to decide whether GSK’s previously approved multiple myeloma drug that was withdrawn from the market in 2022 should be approved again for use in combination with BorDex or PomDex. Meanwhile, Japan today became the second major regulator to approve the Blenrep combinations.